Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly

In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

75 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Rouen, Rouen, Bois Guillaume, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 75 years and over identified as having Alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine

Exclusion criteria

Patients with decompensated chronic condition or acute phase disease

Treatment and study plan

Primary outcomes

To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine

Time frame: 2 years

Secondary outcomes

To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence.

Time frame: 2 years

Sponsors and collaborators

Lead sponsor

University Hospital, Limoges

Other

Registry information

Official study title

Inappropriate Medications and Alzheimer Disease: Prevalence and Associated Factors in Elderly Patients Treated With Anticholinesterase and/or Memantine. MIDA Study.

Acronym: MIDA

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2012
First posted: Aug 7, 2009
Registry last updated: Mar 20, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed